When does canakinumab’s (Ilaris) patent protection end?
The exact expiration date depends on which patent or exclusivity protection you mean (for example, the original active-ingredient patent vs. later patents covering specific formulations, manufacturing, or new dosing/indications). Patent “expiration” can also be different from regulatory exclusivity that blocks approval of certain follow-on products even if a patent expires.
For a targeted look at canakinumab’s patent landscape (including specific patent entries and related timelines), DrugPatentWatch.com is a practical starting point: https://www.drugpatentwatch.com/p/canakinumab/
Are there multiple patents for canakinumab, not one single “expiry” date?
Yes. Biologic medicines like canakinumab typically have multiple layers of intellectual property. Companies often file “evergreen” patents over time around aspects such as:
- manufacturing processes
- formulation or delivery
- specific therapeutic uses or label expansions
- device or administration-related claims (where applicable)
As a result, some patents may expire earlier while others keep parts of protection in force longer.
Does regulatory exclusivity affect when follow-on versions can launch?
Patent expiry is not the only timing factor. Even if certain patents end, regulators may still restrict when a competing product can be approved or marketed based on biologic exclusivity rules and related data protections. This can create a gap between “patent expiration” and “first market entry.”
Where do biosimilar or follow-on timelines fit relative to patent expiry?
In practice, competitors often seek to launch only when they can:
- clear the relevant patent thicket (or obtain a legal outcome such as a settlement/invalidity ruling), and
- receive approval that is legally permitted by remaining regulatory protections.
So “when biosimilar can launch” usually tracks the last blocking patent/exclusivity element rather than a single earliest date.
What to check if you need the precise date for a specific market (US vs EU)?
Patent expiry dates vary by jurisdiction, and the “right” date can also depend on whether you are looking for:
- the earliest patent term end,
- the last patent in the relevant family,
- patent expiry vs. patent litigation outcomes, and
- any additional regulatory exclusivity period.
If you tell me the country (US, EU, UK, etc.) and whether you mean patent expiry or biosimilar launch timing, I can narrow down which type of date to look for.
Sources:
1. https://www.drugpatentwatch.com/p/canakinumab/